SYDNEY, Australia, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced its participation in various upcoming industry conferences.
The Company will be presenting updated clinical data from the Phase I TACTI-mel trial in metastatic melanoma for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) and new data relating to its pre-clinical product candidate, IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases, at industry conferences in March 2019.
|Conference:||World Immunotherapy Congress USA 2019|
|Dates:||3-5 March 2019|
|Venue:||Grand Hyatt, San Diego, USA|
|Presentation Title:||Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients|
|Presenter:||Dr. Frédéric Triebel, CSO and CMO of Immutep|
|Conference:||14th Congress of ECCO (European Crohn’s and Colitis Organisation)|
|Dates:||6-9 March 2019|
|Venue:||Bella Center, Copenhagen, Denmark|
|Presentation Title:||IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases|
|Presenter:||Mathieu Angin, Phd, Immutep Research Scientist|
All presentations will be made available on the Company’s website.
Immutep is listed on the Australian Stock Exchange (IMM), and on the NASDAQ (IMMP) in the US.
Further information can be found on the Company’s website www.immutep.com or by contacting:
Jay Campbell, Chief Business Officer, Immutep Limited
+1 (917) 860-9404; email@example.com
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; firstname.lastname@example.org
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; email@example.com